LCM
IKT icon

Lynwood Capital Management’s Inhibikase Therapeutics IKT Stock Holding History

Lynwood Capital Management’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-20,000
Closed -$178K – 150
2022
Q1 		$178K Sell
20,000
-22,500
-53% -$181K 0.19% 90
2021
Q4 		$375K Buy
+42,500
New +$469K 0.36% 67

Other funds holding IKT

ACM
ACT Capital Management Wayne, Pennsylvania $153M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AC
Antara Capital New York $30.2K AUM 5.24% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
HLA
Hamilton Lane Advisors Conshohocken, Pennsylvania $149M AUM 14.17% 1-Year Est. Return
RAM
Redmond Asset Management Henrico, Virginia $401M AUM 14.95% 1-Year Est. Return
ZCA
Zeke Capital Advisors Berwyn, Pennsylvania $1.53B AUM 17.37% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Koshinski Asset Management
Koshinski Asset Management Decatur, Illinois $1.88B AUM 29.07% 1-Year Est. Return

Lynwood Capital Management's IKT Position: Q2 2022 in Review

Lynwood Capital Management sold out of Inhibikase Therapeutics (IKT) in Q2 2022, closing a stake of 20,000 shares — an estimated $178K sold.

Lynwood Capital Management first reported a position in IKT in Q4 2021 and held it in 2 quarters. The position peaked at $375K in Q4 2021. 22 funds tracked by Wall St. Rank hold IKT as of Q2 2022.

  • Lynwood Capital Management reported no remaining Inhibikase Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Lynwood Capital Management sold 20,000 Inhibikase Therapeutics shares in Q2 2022, an estimated $178K.
  • Lynwood Capital Management first reported a position in Inhibikase Therapeutics in Q4 2021 and held it in 2 quarters.
  • Lynwood Capital Management's Inhibikase Therapeutics position peaked at $375K in Q4 2021.
  • 22 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q2 2022.

Based on Lynwood Capital Management's 13F filing for Q2 2022, filed 2 Aug 2022.